Business Context and Reporting Period
This Form 8-K is filed by Vital Therapies, Inc. (noted as Immunics, Inc. in metadata) for the reporting period of October 25, 2018. The filing addresses a regulatory notice received from The Nasdaq Stock Market LLC regarding the company's stock listing status.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on stock price compliance rather than operational financial performance.
Material Changes
The material change reported is the receipt of a notice from Nasdaq stating the company is not in compliance with Listing Rule 5450(a)(1), the Minimum Bid Price Rule. This non-compliance occurred because the common stock failed to maintain a minimum closing bid price of $1.00 for 30 consecutive business days.
Outlook, Risks, and Contingencies
- Compliance Period: The company has 180 calendar days, until April 23, 2019, to regain compliance.
- Remediation Path: Compliance can be achieved if the bid price closes at $1.00 per share or more for a minimum of 10 consecutive business days before the deadline.
- Delisting Risk: If compliance is not regained, the stock faces delisting from the Nasdaq Global Select Market unless the company requests a hearing before a Nasdaq Hearings Panel.
- Immediate Impact: The notice has no immediate effect on the listing or trading of the common stock.
Investor Verification Checklist
- Verify the current closing bid price of Vital Therapies, Inc. common stock to assess proximity to the $1.00 threshold.
- Monitor the company's progress toward achieving 10 consecutive days of closing prices at or above $1.00 before April 23, 2019.
- Check for any subsequent filings regarding a request for a hearing before a Nasdaq Hearings Panel if the compliance period expires without meeting the price requirement.